telisotuzumab adizutecan + osimertinib

**Telisotuzumab adizutecan + osimertinib** is a combination investigational regimen comprised of telisotuzumab adizutecan, an antibody-drug conjugate targeting the c-Met protein, and osimertinib, a third-generation small molecule EGFR tyrosine kinase inhibitor. Telisotuzumab adizutecan delivers a cytotoxic payload to cells overexpressing c-Met, promoting cell death independently of MET pathway signaling[1][5]. Osimertinib blocks the activity of mutant epidermal growth factor receptor (EGFR), including T790M resistance mutations, suppressing tumor cell proliferation and survival[2][4][6]. This combination is primarily being evaluated for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC) with specific genetic alterations, including high c-Met expression and EGFR mutations, though clinical trials may extend to other solid tumors.

Other names

telisotuzumab adizutecanosimertinib